News

Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for ...
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...
The regulator's review comes after the French medicines agency raised questions about the effectiveness of a generic drug ...
Novo Nordisk NVO announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has ...
A new gene therapy delivery device could let hospital pharmacies make personalized nanomedicines to order. This democratized ...
The 12th edition of the European Pharmacopoeia will be an all-digital, redesigned, user-friendly issue.
European CE mark approval of the entire FemBloc® system marks pivotal achievement in expanding safe, accessible and ...
First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025; Marks the ...
Siena: Sun Pharma European partner Philogen S.p.A has voluntarily withdrawn the application for marketing authorization to ...
A new gene therapy delivery device could let hospital pharmacies make personalized nanomedicines to order. This democratized approach to precision medicine, as published in Frontiers in Science, could ...
The marketing authorisation application (MAA) for Nidlegy was submitted in June 2024, but Philogen decided to withdraw it due ...
The European Medicines Agency has begun a review of medicines to treat alcohol dependency that contain sodium oxybate, it ...